Another FLT3 mutation associated marker profile (sCD3-/CD117+/CD34+/CD62L+/CD56-/CD2+/CD7+/CD1a-/CD4-/CD5-/CD8-/CD13+ [36] can be adopted to 71% (17/24) of our FLT3mut ETP-ALL patients; this profile was highly specific for FLT3 mutations without a false prediction. This evidence concerns the gene SELL and acute lymphoblastic leukemia.